Table 3.

Follow‐up and Outcome After PTA in 235 Patients With Steatotic (n = 52) and Nonsteatotic HCCs (n = 183) Small HCC Nodules

	Steatotic HCC	Non‐steatotic HCC	P Value
Follow‐up (median, 95% CI)	27.5 months (20.6‐34.8)	29.1 months (25.2‐33.6)	0.54
Liver transplant (n [%])	6 (11.5%)	20 (10.9%)	0.9
Death, all causes (n [%])	2 (3.8%)	43 (23.5%)	0.001
HCC‐related death (n [%])	0	26 (14.2%)	0.002
Death from liver cause, except HCC (n [%])	2 (3.8%)	8 (4.4%)	0.62
Overall recurrence (n [%])	22 (42.3%)	100 (54.6%)	0.16
Early (<2 years) recurrence (n [%])	17 (32.7%)	90 (49.2%)	0.041
First distant recurrence beyond Milan criteria (n [%])	3 (5.8%)	17 (8.5%)	0.58
LTP, per tumor
Occurrence (n [%])	5 (7.6%)	55 (15.5%)	0.12
Time to LTP (mean ± SD)	18.9 ± 12 months	12.1 ± 8.7 months	0.18
IDR, per patient
Occurrence (%)	21 (40.4%)	90 (49.2%)	0.27
Time to IDR (mean ± SD)	16.4 ± 13.1 months	9 ± 8.7 months	0.006
Largest HCC nodule (mean ± SD)	18 ± 7 mm	17 ± 12 mm	0.81
AFP score > 2 at first IDR (n [%])	1 (1.9%)	6 (3.3%)	1
Curative treatment of IDR	16 (72.7%)	51 (56.7%)	0.23
Extrahepatic recurrence (n [%])	1 (1.9%)	17 (9.3%)	0.13

Unless otherwise indicated, data are presented per patient.

Significant P values are indicated in bold.